Products
By Team
Sales
Multithread effectively and personalize outreach to convert deals faster
Social Media Marketing
Elevate social presence and drive business growth from social media
RevOps
Identify and prioritize high-intent leads, and improve sales effectiveness
Events & Field Marketing
Find and connect with ICP attendees, and improve event outcomes
Resources
.png)
.png)
fate therapeutics
Overview
Fate Therapeutics is a clinical-stage biopharmaceutical company at the forefront of developing off-the-shelf, iPSC-derived cell therapies for cancer and immune disorders. Leveraging induced pluripotent stem cell (iPSC) technology, Fate Therapeutics is pioneering a novel approach to cell therapy, moving away from patient-specific treatments towards scalable, allogeneic solutions. Their focus is on engineering master iPSC lines to generate consistent and readily available cell therapies, positioning them as a key innovator in the rapidly evolving allogeneic cell therapy market. They are actively engaged in clinical trials, aiming to demonstrate the efficacy and safety of their iPSC-derived NK cell and T-cell therapies across a range of hematologic malignancies and solid tumors.
fate therapeutics's headcount breakdown by department
| Department | HeadCount |
|---|---|
Administrative | 9 |
Consulting | 1 |
Service | 0 |
Design | 0 |
Education | 1 |
Finance | 4 |
Management | 10 |
Hr | 2 |
Legal | 7 |
Marketing | 0 |
Medical | 3 |
Operations | 26 |
Department | 39 |
Product | 2 |
Management | 2 |
Estate | 0 |
Research | 63 |
Sales | 0 |
Technical | 10 |
Trades | 0 |
The departmental structure at Fate Therapeutics clearly indicates a company deeply rooted in research and development, with a strong emphasis on manufacturing and operational excellence. The substantial Research department (63 employees), representing over a quarter of the workforce, highlights the company's commitment to scientific innovation and advancing their iPSC-derived cell therapy platform. The significant investment in Operations (26 employees) reflects the complexity and rigor required for cell therapy manufacturing, encompassing cell culture, genetic engineering, and quality control. While 'Other Department' (39 employees) remains somewhat vague, it likely encompasses critical functions related to process development, quality assurance, and preclinical research, which are vital for translating research findings into clinical-grade products. The relatively smaller size of support functions such as Administrative (9), HR (2), Finance (4), and Legal (7) suggests a lean management structure, allowing for efficient allocation of resources towards core scientific and operational activities. The absence of dedicated Sales and Marketing departments suggests that Fate Therapeutics is currently prioritizing clinical development and strategic partnerships for future commercialization efforts. This departmental distribution aligns with a biopharmaceutical company in its clinical-stage, focused on demonstrating clinical efficacy and scaling up manufacturing capabilities for potential future product launches, while strategically outsourcing or partnering for commercial activities.
fate therapeutics's employees by locations
Employee Count by Country
Total: 179 employees
Fate Therapeutics exhibits a highly concentrated geographic footprint, with the vast majority of its workforce (178 employees) located within the United States. This domestic focus underscores the company's reliance on the established biotech infrastructure, skilled talent pool, and favorable regulatory environment within the US for its core research, development, and manufacturing activities. The presence of a single employee in China indicates a very limited international presence, potentially supporting regulatory affairs, partnership management, or early-stage market exploration in that region. This US-centric approach is common for biopharmaceutical companies in the clinical stage, as they prioritize demonstrating clinical efficacy and securing regulatory approval in their home market before expanding internationally. As Fate Therapeutics progresses through clinical trials and approaches commercialization, it may strategically expand its geographic footprint to include key markets in Europe and Asia. However, at present, its geographic strategy is primarily focused on leveraging the resources and opportunities available within the United States to advance its iPSC-derived cell therapy pipeline.
Want to stay ahead of fate therapeutics's org changes?
Get alerts when hiring spikes or teams shift focus
Track changes vs. competitors
Spot warm GTM signals early